RXDX 105

Drug Profile

RXDX 105

Alternative Names: AC 013773; CEP-32496; RXDX-105

Latest Information Update: 26 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ambit Biosciences Corporation; Cephalon
  • Developer Ignyta
  • Class Antineoplastics; Isoxazoles; Phenyl ethers; Phenylurea compounds; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 11 Sep 2017 Updated efficacy data from a phase I/Ib trial in Solid tumours presented at the 42nd European Society for Medical Oncology (ESMO-2017)
  • 11 Sep 2017 Ignyta completes enrolment in its phase I/Ib trial for Solid tumours in USA (NCT01877811)
  • 14 Aug 2017 Ignyta temporarily suspends an expanded access to RXDX 105 for Cancer in USA (NCT03052569)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top